BioSite, Eli Lilly To Team Up For More Personalized Sepsis Therapy

BioSite is working to get 510(k) clearance for a new point-of-care diagnostic in time to participate in a clinical trial of Eli Lilly's sepsis therapy drug Xigris, Biosite said March 20. The trial is scheduled to begin later this year